• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

    2.125 +0.155 (+7.87%)
    Streaming Delayed Price Updated: 3:45 PM EDT, Oct 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tiziana Life Sciences Ltd - Common Shares

    < Previous 1 2 3 4 5 Next >
    Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Purchase of Shares by Chairman
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences to Present at the Bio International Convention
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Purchase of Shares by Chairman
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences to Present at the 37th Annual Roth Conference
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences not to engage in capital raising activities for the immediate future
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
    From Tiziana Life Sciences Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.